Results 81 to 90 of about 194,291 (245)

Tacrolimus-induced Ascites after Liver Transplant

open access: yesInternational Journal of Organ Transplantation Medicine, 2018
Massive post-transplantation ascites is a rare but serious condition following liver transplantation. Although, many etiologies are suggested as the cause of this complication, in some cases the definitive etiology remains unknown.
M Hosseini   +4 more
doaj  

Single‐Cell Dissection of Therapy‐Induced Remodeling Uncovers a Fibroblast‐Driven Immunosuppressive Niche and Targetable Vulnerabilities in Lethal Prostate Cancer

open access: yesAdvanced Science, EarlyView.
Single‐cell longitudinal profiling reveals that androgen‐deprivation therapy induces a DPT+ fibroblast‐complement axis that suppresses macrophage inflammation and drives CD8+ T cell exhaustion in prostate cancer. Concurrently, resistant epithelial subpopulations persist and engage TSPAN1‐ and NRXN1‐mediated programs promoting CRPC and neuroendocrine ...
Yang Chen   +19 more
wiley   +1 more source

Pattern and associated factors of adherence to immunosuppressive medications in kidney transplant recipients at a referral center in Iran

open access: yesPatient Preference and Adherence, 2019
Omid Moradi,1 Iman Karimzadeh,2 Dorna Davani-Davari,2 Mojtaba Shafiekhani,2 Mohammad Mahdi Sagheb31Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran; 2Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University ...
Moradi O   +4 more
doaj  

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

open access: yesAdvanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun   +15 more
wiley   +1 more source

Pharmacokinetics of immunosuppressive agents during hemoperfusion in a sheep model. [PDF]

open access: yesFront Med (Lausanne), 2023
Leber B   +7 more
europepmc   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang   +8 more
wiley   +1 more source

Light‐Activatable Nitric Oxide Release via Intramolecular Electron Transfer for Tumor Pyroptosis Induction

open access: yesAdvanced Science, EarlyView.
This work proposes a novel strategy to fabricate unimolecular pyroptosis photoinitiators activated by deep‐red light at low light doses. It relies on a photosensitization mechanism to trigger nitric oxide (NO) release from benzisothiadiazole‐based N‐nitrosanilines without modification of nitro moieties, thereby boosting pyroptosis‐mediated ...
Chuangxin Zhang   +4 more
wiley   +1 more source

Bifidobacterium Pseudolongum‐Derived Inosine Mitigates Polystyrene Nanoplastics‐Induced Hepatic Injury by Inhibiting the Polarization of M1 Macrophages

open access: yesAdvanced Science, EarlyView.
Probiotic B.p colonization elevated gut‐derived inosine level in the liver, while elevated inosine activated A2AR and subsequently blocked NPs‐induced polarization of M1 macrophages by repressing the miR155/SOCS1/NF‐κB pathway. This reduced the release of inflammatory cytokines and thereby, mitigated NPs‐induced hepatic injury.
Kaikai Zhang   +10 more
wiley   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

open access: yesAdvanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy